Harrow, Inc. (HROW)

Market Cap	1.25B +42.1%
Revenue (ttm)	272.30M +36.4%
Net Income	-5.14M
EPS	-0.14
Shares Out	37.23M
PE Ratio	n/a
Forward PE	72.19
Dividend	n/a
Ex-Dividend Date	n/a

Volume	379,356
Open	34.87
Previous Close	33.28
Day's Range	33.03 - 34.90
52-Week Range	20.85 - 54.85
Beta	0.10
Analysts	Strong Buy
Price Target	71.14 (+111.73%)
Earnings Date	Mar 2, 2026

About HROW

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1998
• Employees: 373
• Stock Exchange: NASDAQ
• Ticker Symbol: HROW
• Website: https://www.harrow.com

Financial Performance

In 2025, Harrow's revenue was $272.30 million, an increase of 36.41% compared to the previous year's $199.61 million. Losses were -$5.14 million, -70.60% less than in 2024.

Analyst Summary

According to 8 analysts, the average rating for HROW stock is "Strong Buy." The 12-month stock price target is $71.14, which is an increase of 111.73% from the latest price.

Price Target

$71.14

(111.73% upside)

Analyst Consensus: Strong Buy